EWM
AZN icon

Evolution Wealth Management’s AstraZeneca AZN Stock Holding History

Evolution Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.94K Hold
20
– – ﹤0.01% 656
2025
Q4 		$3.68K Buy
+20
New +$3.51K ﹤0.01% 582

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Evolution Wealth Management's AZN Position: Q1 2026 in Review

Evolution Wealth Management held its AstraZeneca (AZN) position steady in Q1 2026 at 20 shares worth $3.94K. The position accounts for ﹤0.01% of the portfolio, ranked #656.

Evolution Wealth Management first reported a position in AZN in Q4 2025 and has held it in 2 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Evolution Wealth Management held 20 shares of AstraZeneca worth $3.94K as of Q1 2026.
  • Evolution Wealth Management left its AstraZeneca share count unchanged in Q1 2026.
  • AstraZeneca made up ﹤0.01% of Evolution Wealth Management's portfolio in Q1 2026, its #656 holding.
  • Evolution Wealth Management first reported a position in AstraZeneca in Q4 2025 and has held it in 2 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Evolution Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.